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Abstract
OBJECTIVES.—To develop common indicators, relevant to both EU member states and the 
United States, that characterize and allow for meaningful comparison of antimicrobial stewardship 
programs among different countries and healthcare systems.
DESIGN.—Modified Delphi process.
PARTICIPANTS.—A multinational panel of 20 experts in antimicrobial stewardship.
METHODS.—Potential indicators were rated on the perceived feasibility to implement and 
measure each indicator and clinical importance for optimizing appropriate antimicrobial 
prescribing.
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RESULTS.—The outcome was a set of 33 indicators developed to characterize the infrastructure 
and activities of hospital antimicrobial stewardship programs. Among them 17 indicators were 
considered essential to characterize an antimicrobial stewardship program and therefore were 
included in a core set of indicators. The remaining 16 indicators were considered optional 
indicators and included in a supplemental set.
CONCLUSIONS.—The integration of these indicators in public health surveillance and special 
studies will lead to a better understanding of best practices in antimicrobial stewardship. 
Additionally, future studies can explore the association of hospital antimicrobial stewardship 
programs to antimicrobial use and resistance.
Appropriate antimicrobial use is associated with improved patient outcomes and decreased 
risk of adverse events, including development of antimicrobial resistance and Clostridium 
difficile infection.1–3 To this aim, many healthcare and professional organizations advocate 
for coordinated programs that implement activities to ensure appropriate antimicrobial 
prescribing.4–7 Such programs are referred to as antimicrobial stewardship programs 
(ASPs), or simply antibiotic stewardship. Antimicrobial stewardship is a key prevention 
strategy to address the global concern of increasing antimicrobial resistance.8,9 Preservation 
of effective antimicrobial agents is an international public health issue; therefore, 
implementation of ASPs in hospitals is a focus of healthcare systems and governments in 
many countries.5,10,11
The Transatlantic Taskforce on Antimicrobial Resistance (TATFAR) was established by a 
2009 US-EU summit declaration to enhance cooperation to address antimicrobial resistance.
12,13
 One key focus area of this collaboration is the appropriate therapeutic use of 
antimicrobial drugs. Recognizing that a common way to assess ASPs is needed to 
understand and promote effective antimicrobial stewardship, in a 2011 report, TATFAR 
recommended the development of common structure and process indicators for hospital 
ASPs.14 Using common indicators, EU member states and the United States could 
meaningfully characterize and compare antimicrobial stewardship efforts among different 
countries and healthcare systems.
Assessments of antimicrobial stewardship practices have been conducted in EU member 
states15–18 and in the United States19–21 but vary in terms of focus, length, and applicability 
to other health systems. The objective of this effort was to learn from and build upon these 
previous assessments in order to create a manageable number of ASP indicators that are 
relevant and feasible for comparison. To meet this objective, experts in hospital 
antimicrobial stewardship developed a set of indicators to describe the structure and 
functions of ASPs across healthcare systems.
METHODS
Participants
Antimicrobial stewardship experts from the European Union and the United States were 
recruited to participate in a modified Delphi process. Purposive sampling was used to ensure 
participants (experts) had the necessary expertise and experience for the development of the 
indicators, knowledge about clinical and public health practice, and diversity in geography 
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and healthcare systems. All 20 invited experts participated in the rating of indicators, 
including the project coordinators from the European Centre for Disease Prevention and 
Control (ECDC) and the US Centers for Disease Control and Prevention (CDC). The panel 
had multidisciplinary representation from 9 EU member states and 6 US states (Table 1 and 
list of members at end of text).
Consensus Process
A modified Delphi process using the RAND/UCLA appropriateness method was followed to 
build consensus using self-administered questionnaires with email exchange among the 
experts.22 An initial list of 53 indicators was developed from the Cochrane systematic 
review of interventions to improve antibiotic prescribing practices for hospital inpatients by 
Davey et al1 as well as previously developed structure and process indicators, antimicrobial 
stewardship surveys, and antimicrobial stewardship guidelines in the European Union and 
United States.15–21 In addition, the project coordinators conducted a comprehensive, 
nonsystematic review of antimicrobial stewardship literature published from 2006 to 2013.
In the first rating round, experts were asked whether to “retain” or “remove” each indicator 
on its ability and feasibility to characterize ASPs. Indicators for which more than 60% of 
experts marked “retain” continued on to a second round. Next, the experts rated each of the 
structure and process indicators on a Likert scale from 1 to 9, where 1 indicated “Strongly 
disagree” and 9 indicated “Strongly agree,” according to 3 criteria: feasibility (ie, it would 
be possible to implement and measure this indicator at the facility level); clinical 
importance (ie, this indicator is important for optimizing the appropriateness of 
antimicrobial prescribing); and relevance to minimizing antimicrobial resistance (ie, this 
indicator is relevant to reducing the development of antimicrobial resistance). The median 
values of responses for feasibility and clinical importance were summed and indicators with 
a combined median score of 14 or greater were retained. Based on the RAND/UCLA 
appropriateness methods, agreement in ratings among experts was measured using an 
agreement score defined as the interpercentile range adjusted for symmetry minus the 
interpercentile range (ie, interpercentile range adjusted for symmetry – interpercentile 
range).22 A 90/10 interpercentile range was used for better discriminating power and 
agreement was defined as an agreement score greater than 0. The results were analyzed 
using an electronic spreadsheet (Excel; Microsoft). After the first and second rounds, 
members of the expert panel received feedback on the rating and agreement for each 
indicator, then participated in a conference call with a trained facilitator who moderated a 
structured discussion focusing on indicators with low agreement scores among the ratings, 
borderline combined median scores (12–14), and low median ratings for clinical importance. 
In a third and final round, experts re-rated the structure and process indicators. The changes 
in median and agreement score from the second to the third round were determined for each 
indicator. Also, agreement scores after the second and third round were compared by the 
Wilcoxon signed rank test to assess consensus. The experts were also asked to indicate 
whether each indicator should be included as either a “core” indicator (necessary to 
characterize ASPs) or a “supplemental” indicator (not necessary but desirable); or removed.
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An in-person expert consensus meeting moderated by the project coordinators took place 
following the third round in Stockholm, Sweden, on June 18, 2014. At this meeting, experts 
reviewed and discussed the indicators that at least 20% of experts marked for removal in the 
third round. If consensus about removal was not achieved, the indicator would be carried 
over to the supplemental indicators group. Next, experts examined the supplemental 
indicators and discussed whether any should be reclassified as core or be removed. Finally, 
the indicators that emerged as core and supplemental during the meeting were reexamined 
with attention on their utility to comprehensively describe hospital ASPs and be understood 
in a multinational context. Final decisions regarding classification and wording of indicators 
were made by consensus.
RESULTS
In March 2014, 20 invited experts (100%) responded to the first round. Of the 53 proposed 
structure and process indicators, 36 were retained (10 with revision) and 17 were removed 
(Table 2). In response to feedback that the proposed indicators focused on ASP staffing and 
activities (structure), but did not capture the extent of activity performance (process), 8 
process indicators were added to the second round of rating (Table 3). Two separate 
indicators, having an infection preventionist and a hospital epidemiologist on the 
antimicrobial stewardship team, were merged.
Nineteen experts (95%) rated the 44 indicators carried forward to the second round. The 
mean (range) scores for feasibility and clinical importance for all indicators combined were 
7.5 (5–9) and 7.6 (6–9), respectively. The experts rated indicators related to having a 
cumulative antimicrobial susceptibility report and guidelines high for both feasibility and 
clinical importance; whereas those related to governance and management and policies were 
generally rated higher for feasibility than for clinical importance; and indicators related to 
activities and interventions were generally rated higher for clinical importance than for 
feasibility (Table 2). For relevance to minimizing antimicrobial resistance, no indicator had a 
median score higher than 7 and there was low agreement on the scoring of the indicators 
among the experts (data not shown), so rating of relevance to minimizing antimicrobial 
resistance was not repeated in the third round. Following the second round, 14 experts (70%) 
participated in a group call on which many remarked that agreement or disagreement in 
feasibility ratings might be related to differences in healthcare settings and systems more 
than to discordant expert opinion. Variation in the information technology (IT) capacity 
among healthcare systems (eg, technical equipment, electronic systems) led to discussion on 
whether to remove the IT indicators or refocus the domain in more general terms. Some 
experts expressed that IT indicators are drivers for improvement and should be retained to 
track growth in the future, even if some countries or systems may not yet have advanced IT 
capacity for ASPs.
After analysis of the second round ratings and input from the expert panel call, 37 of the 44 
proposed structure and process indicators were retained. An indicator that combined 
assessment of compliance with community-acquired pneumonia and urinary tract infection 
guidelines was divided into 2 separate indicators, making a total of 38 indicators advancing 
to third round (Tables 2 and 3). Six indicators were removed: 2 human resources indicators 
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(involvement of IT staff and quality improvement staff); 2 indicators related to IT (presence 
of an IT system for prescribing and its application to clinical decision support for 
antimicrobial prescribing); the indicator on routine use of antimicrobial order forms and the 
indicator about dedicated time for clinical teams to review antimicrobial orders. For the 
proposed process indicators, the experts expressed that 95% compliance with guidelines was 
too stringent and recommended that the threshold change to 80%.
The response rate for the third round was 95% (19/20 experts). The mean (range) scores for 
feasibility and clinical importance were 7.5 (6–9) and 7.8 (6–9), respectively. The indicators 
with highest agreement for feasibility among experts were the identification of a defined 
ASP, formulary, and surgical prophylaxis guidelines; whereas the indicators with lowest 
agreement on feasibility were process indicators that assessed whether “>80% of sampled 
cases” had a documented indication or followed facility-specific guidelines. For clinical 
importance, the indicators on physician and pharmacist leadership, IT capability, facility-
specific treatment guidelines, and postprescription review and feedback had high agreement 
in scoring among experts; whereas the human resources indicators not related to leadership, 
the discontinuation of specified antimicrobial prescriptions after a predefined duration, and 
the capture of indication for treatment in the medical record had the lowest agreement scores 
(Table 3). The mean agreement score increased from 1.8 to 2.9 for feasibility (P = .007) and 
from 2.9 to 3.3 for clinical significance (P = .087).
Thirteen experts (65%), with balanced representation from the European Union and United 
States, attended the in-person expert consensus meeting. There was consensus that indicators 
that at least 70% of experts rated as “core” would be core indicators, with minor revisions to 
clarify definitions. Most experts at the meeting recommended removal of the indicators that 
assessed compliance with facility-specific community-acquired pneumonia and urinary tract 
infection guidelines in at least 80% of sampled cases for the following reasons: there were 
concerns about feasibility; collection of such data would increase workload; accurate 
quantification would be challenging; and the indicator may not reflect appropriateness of 
non–guideline-concordant clinical decisions. Similarly, documentation of an indication for 
treatment in at least 80% of sampled cases was rejected. Some experts noted that monitoring 
other aspects of antimicrobial prescribing rather than attempting to quantify compliance may 
be a more effective use of the time of those responsible for antimicrobial stewardship. 
Experts also recommended removal of “a current susceptibility report has been distributed to 
prescribers” because this indicator does not assess the application of this information to 
patient care nor the ability of prescribers to interpret it; and “does your facility have a 
defined formulary of antimicrobial agents?” because the term formulary was found to have 
different interpretations, and diversity in prescribing may be considered as an approach to 
prevention of antimicrobial resistance.23,24 In contrast to recommending removing the 
assessment of compliance with community-acquired pneumonia and urinary tract infection 
guidelines, EU experts strongly advocated for the monitoring of surgical prophylaxis as a 
core indicator. The feasibility of this indicator is supported by current measurement in the 
United States through the Surgical Care Improvement Project and in the European Union by 
the Healthcare-Associated Infections Network as well as longstanding experience at national 
level.25–28 Therefore, review of surgical prophylaxis was reclassified from a supplemental to 
a core indicator and the quantification of guideline concordance became a supplemental 
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indicator. Experts who were not able to participate in the in-person meeting were provided 
all materials before the meeting and a summary. Each expert had the opportunity to give 
input into the final indicators and report developed after the meeting. At the conclusion, 
there were 17 core indicators (Tables 3 and 4) and 16 supplemental indicators (Table 3).
DISCUSSION
A multinational panel of experts in antimicrobial stewardship developed a set of indicators 
to characterize the infrastructure and activities of hospital ASPs using standardized methods 
to address the TATFAR recommendation to develop common structure and process 
indicators for hospital ASPs. The modified Delphi process reflected the input of experienced 
clinical and public health professionals with diverse perspectives and fostered an exchange 
of best practices to address antimicrobial resistance and appropriate use of antimicrobial 
agents among diverse health systems. The high ratings of feasibility and clinical importance 
of each indicator along with convergence of ratings between multiple rounds demonstrate 
that the final indicators are likely to be practical in diverse settings and meaningful to quality 
of care.
Themes that emerged during the expert consensus meeting were the necessity of support and 
accountability for antimicrobial stewardship activities. Salary support was specified to 
differentiate a higher level of support than mere inclusion of responsibilities for 
antimicrobial stewardship in job duties without salary support. Participants acknowledged 
the importance of multidisciplinary involvement, but given that the specific composition of 
teams was highly variable among healthcare systems and facilities within the same system, 
indicators that asked about specific staff roles were retained as supplemental rather than core 
indicators. Participants noted that active feedback was more effective in changing 
prescribing practices compared with passive education of prescribers; therefore, direct 
communication of antimicrobial audits or reviews to prescribers was deemed core and 
education on improving prescribing was removed. An annual report on antimicrobial 
stewardship and an indicator related to IT capability remained as core indicators because 
they were seen as “reach” goals—that is, indicators that may be advanced for the current 
state of ASPs in most facilities but could, in the future, differentiate ASPs and set a target for 
achievement.
The proposed indicators build upon similar efforts to assess the hospital ASPs in France, 
Germany, the United Kingdom, the United States, and the European Commission–sponsored 
Antibiotic Strategy International.5,15–18,29,30 Experts involved in the development, 
implementation, and analysis of many of these ASP assessment efforts participated in this 
process. The TATFAR ASP indicators align and could be compared with many questions in 
these previous assessments provided that an acceptable balance between flexibility and 
consistency in translation is achieved. By design, the TATFAR core indicators are a smaller 
number of items suitable for public health surveillance or integration with special studies, 
such as the European Surveillance of Antimicrobial Consumption Network coordinated by 
ECDC or point prevalence surveys of antimicrobial use conducted by the ECDC or the CDC 
or within large health systems. The CDC has developed a guidance document, Core 
Elements of Hospital Antimicrobial Stewardship, that aligns with the TATFAR ASP 
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indicators and has incorporated antimicrobial stewardship questions based on the indicators 
into the 2015 National Healthcare Safety Network Annual Hospital Survey of more than 
4,000 US facilities.31,32 Similarly, the ECDC is planning to include questions based on the 
TATFAR ASP indicators into its second point prevalence survey of healthcare-associated 
infections and antimicrobial use in European acute care hospitals that will take place in 
2016–2017.
Most of the final indicators are structure rather than process indicators, reflecting the critical 
importance of staffing, baseline capacity, and support for ASPs as well as the variability of 
ASP implementation in healthcare. The establishment of a well-supported, multidisciplinary 
ASP infrastructure ensures an ASP is sustainably integrated into facility practices rather than 
dependent on a single person. The evidence base for any individual structure and process 
indicator is limited and challenging to establish because antimicrobial stewardship activities 
are multifaceted and involve a combination of efforts to attain results. Hopefully, as 
guidelines for ASPs are developed and adopted, metrics of appropriate antimicrobial use 
will also be developed as accurate process indicators of ASPs.33 Although minimizing 
antimicrobial resistance is a primary goal of TATFAR and was initially included as a rating 
criterion in this process, the ratings of these indicators were low and highly divergent. This 
result reflects the challenge of establishing the impact of ASPs on antimicrobial resistance.34 
Other metrics of ASP success such as antimicrobial use and patient-focused outcomes are 
critical to demonstrate the impact of ASPs. Outcome indicators for ASPs were not evaluated 
as part of this modified Delphi process and expert consensus because standards for 
measuring antimicrobial use in hospital settings are the objective of a separate TATFAR 
recommendation.35
The modified Delphi process is a widely used, standardized method to develop healthcare 
quality indicators that ensures equal representation among participants and allows for input 
and collective consensus across diverse geographic locations. This method provides multiple 
opportunities for clarification and revision throughout the iterative process of rating and 
soliciting comments. Additionally, the expert panel group call and in-person consensus 
meeting contributed greatly to developing a common understanding and reaching final 
consensus, and included input from the 7 experts who were unable to travel to participate in 
the final consensus meeting. Potential limitations were that individual ratings by the experts 
were self-reported and subject to personal perspectives or experiences. A formal systematic 
review was not within the scope of this project.36 The project did not include representation 
from countries other than Europe and the United States owing to scope established in the 
2009 US-EU Summit declaration. The entire process was conducted in English, which may 
have created a cultural bias or limited the participation of those who did not feel most 
comfortable exchanging views in English. Although the final indicators could offer a starting 
point for developing international ASP indicators, their relevance and applicability to Latin 
American, African, Asian, and other countries is unknown.
In conclusion, core and supplemental indicators of ASPs deemed to be essential elements to 
ensuring appropriate use of antimicrobial agents in the hospital setting were developed by a 
multinational group of experts through a modified Delphi process and consensus meeting. 
The collaborative development of these structure and process indicators for TATFAR 
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contributed to mutual understanding of the capacity and vision for hospital ASPs in EU 
member states and in the United States. Implementation of these TATFAR-developed core 
indicators in multiple countries could contribute to a comprehensive, comparative 
description of infrastructure, policies, and practices of antimicrobial stewardship 
internationally. These findings could, in turn, lead to an understanding of best practices of 
ASPs through further investigation into the relation of different antimicrobial stewardship 
approaches to antimicrobial use and resistance. We believe that these indicators define clear 
expectations for hospital ASPs and, through piloting, implementation, and evaluation, will 
contribute to the understanding of ASP practices in hospitals and improve antimicrobial 
prescribing. A full report with a more detailed summary of the process and results of the 
ratings by rounds is available from the TATFAR Secretariat 
(TATFAR_Secretariat@cdc.gov).
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table 1.
Characteristics of 20 Experts Who Participated in the Modified Delphi Process to Develop Antimicrobial 
Stewardship Program Structure and Process Indicators
Characteristic N (%)
Current country of residence
 European Uniona 13 65
 United States 7 35
Professional training
 Medicine 15 75
 Pharmacy 3 15
 Microbiology 1 5
 Psychology and business administration 1 5
Current profession
 Clinical medicine 11 55
 Pharmacy 3 15
 Public health 6 30
NOTE. The experts had a mean of 17 years of experience in antimicrobial stewardship.
aAustria, Belgium, England, France, Germany, Greece, Italy, Netherlands, Scotland (2), Slovenia, Sweden (2).
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table 2.
Summary of Results From the Modified Delphi Process
Status of indicators N (%)
Indicators rated in the first round 53
 Retained without revision 26 (49.0)
 Retained and revised 10 (18.9)
 Removed 17 (32.1)
 Added 8
Indicators rated in the second round 44
 Retained without revision 26 (59.1)
 Retained and revised 11 (25.0)
 Removed 6 (13.6)
 Added 1
Indicators rated in the third round and Examined at in-person expert consensus meetinga 38
 Retained as “core” indicator without revision 13 (34.2)
 Retained as “core” indicator and revised 4 (10.5)
 Retained as “supplemental” indicator without revision 12 (31.6)
 Retained as “supplemental” indicator and revised 4 (10.5)
 Removed 6 (15.8)
 Added 1
Final indicators 33
 Core indicator 17 (51.5)
 Supplemental indicator 16 (48.5)
a
In the third round, experts were asked whether indicators should be consider “core” (ie, the indicator should be included in a set of indicators for 
ALL hospitals to be asked) or “supplemental” (ie, hospitals can include if the indicator is of interest).
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